Baseline conditions of patients with and without non-steroidal anti-inflammatory drug (NSAID) therapy
| NSAID (n=29) | No NSAID (n=16) | P value | |
| Mean age (SD) | 32 (13) | 37 (13) | 0.15 |
| Male gender, n (%) | 26 (90) | 13 (81) | 0.43 |
| Mean LVEF on CMR (%) | 57 (4) | 55 (6) | 0.09 |
| Body mass index—mean, kg/m2 (SD) | 26 (4) | 27 (4) | 0.5 |
| Smoker, n (%) | 12 (41) | 6 (38) | 1 |
| CAD, n (%) | 2 (7) | 1 (6) | 1 |
| Hypertension, n (%) | 3 (10) | 3 (19) | 0.65 |
| Dyslipidaemia, n (%) | 3 (10) | 3 (19) | 0.65 |
| Diabetes, n (%) | 1 (3) | 0 | 1 |
| Mean troponin (ng/L) | 922 (±1770) | 459 (±580) | 0.18 |
| Mean NT-proBNP (ng/L) | 547 (±489) | 812 (±1744) | 0.48 |
| Mean myoglobin (µg/L) | 87 (±79) | 73 (±101) | 0.22 |
| Mean CRP (mg/L) | 47 (±42) | 42 (±52) | 0.49 |
| Mean leucocytes (G/L) | 8.9 (±2.5) | 8.6 (±3.6) | 0.45 |
| Mean creatinine (µmol/L) | 76 (±11) | 77 (±15) | 0.59 |
| Medications on admission | |||
| Betablocker, n (%) | 0 | 1 (6) | 0.36 |
| ACE inhibitor, n (%) | 3 (10) | 0 | 0.54 |
| ARB, n (%) | 0 | 1 (6) | 0.36 |
| Diuretics, n (%) | 0 | 1 (6) | 0.36 |
| MR-antagonist, n (%) | 0 | 0 | NA |
| Colchicine, n (%) | 0 | 0 | NA |
| Medications at discharge | |||
| Betablocker, n (%) | 5 (17) | 4 (25) | 0.7 |
| ACE inhibitor, n (%) | 12 (40) | 4 (25) | 0.34 |
| ARB, n (%) | 1 (3) | 1 (6) | 1 |
| Diuretics, n (%) | 0 | 1 (6) | 0.36 |
| MR-antagonist, n (%) | 0 | 0 | NA |
| Colchicine, n (%) | 5 (17) | 0 | 0.14 |
ARB, angiotensin receptor blocker; CAD, coronary artery disease; CMR, cardiac MRI; CRP, C reactive protein; LVEF, left ventricular ejection fraction; MR, mineralcorticoid receptor; NT-proBNP, NT-pro-brain natriuretic peptide.